COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03820388
Recruitment Status : Completed
First Posted : January 29, 2019
Last Update Posted : January 29, 2019
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of anesthesia.

Condition or disease Intervention/treatment Phase
Surgery Drug: Propofol 2mg/kg Drug: Etomidate 0.3 mg/kg Drug: Propofol 1 mg/kg Drug: Etomidate 0.15 mg/kg Phase 4

Detailed Description:
Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of anesthesia. The specific aims are testing patient reactions during induction, and in the post-anesthesia care unit (PACU).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients in 3 cohorts will be administered 30 second bolus by manual hand push
Masking: Single (Participant)
Primary Purpose: Supportive Care
Official Title: Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
Actual Study Start Date : December 1, 2017
Actual Primary Completion Date : July 13, 2018
Actual Study Completion Date : July 13, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Propofol Group
Propofol 2 mg/kg
Drug: Propofol 2mg/kg
2 mg/kg
Other Name: Diprivan

Experimental: Etomidate Group
Etomidate 0.3 mg/kg
Drug: Etomidate 0.3 mg/kg
0.3 mg/kg
Other Name: Amidate

Experimental: Propofol plus Etomidate Group
Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
Drug: Propofol 1 mg/kg
1 mg/kg Propofol
Other Name: Diprivan

Drug: Etomidate 0.15 mg/kg
0.15 mg/kg Etomidate
Other Name: Amidate

Primary Outcome Measures :
  1. Blood Pressure [ Time Frame: 10 minutes after induction (intraoperative) ]
    Blood Pressure Fluctuations during Induction; change measured in mmHg

  2. Heart Rate [ Time Frame: 10 minutes after induction (intraoperative) ]
    Heart Rate changes during induction (Beats Per min)

Secondary Outcome Measures :
  1. Pain at injection site [ Time Frame: intraoperative ]
    Pain on injection will be measured using 4 graded scale; 0 = no pain, 1 = verbal complaint of pain, 2 = withdrawal of arm, 3 = both verbal complaint and withdrawal of arm.

  2. Myoclonic movements [ Time Frame: intraoperative ]
    The incidence and degree of myoclonic movements also recorded as follows: 0 = no myoclonic movements, 1 = minor myoclonic movements, 2 = moderate myoclonic movements, 3 = major myoclonic movements.

  3. Post-operative nausea and vomiting [ Time Frame: 24 hours post-operation ]
    Presence of post-operative nausea or vomiting (yes/no).

  4. Vasoactive Agents Use [ Time Frame: 30 minutes post-induction ]
    Frequency of vasoactive agents use to treat adverse reactions of propofol/etomidate.

  5. Sedation depth [ Time Frame: 30 minutes post-induction ]
    Sedation depth using bispectral index (BIS). BIS scores range from 0-100. A value of 0 indicates no EEG activity, 40-60 indicates an appropriate level of general anesthesia, and 90-100 is typical of a state of wakefulness.

  6. Eyelash reflex disappear time [ Time Frame: 1 minute post-induction ]
    Time to disappearance of eyelash reflex after induction.

  7. Intubation time [ Time Frame: 5 minutes ]
    Duration of orotracheal intubation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients scheduled for elective non-cardiac surgery
  • ASA physical status of 2 or 3
  • Age equal to or greater than 18 years old

Exclusion Criteria:

  • Adults unable to provide consent
  • Age less than 18 years old
  • Pregnant women
  • Prisoners
  • Difficult airway
  • Morbid Obesity
  • Preoperative sedation use
  • Severe Cardiac, pulmonary and liver disease
  • Hypotension and shock
  • Emergency surgeries
  • Allergy to propofol or etomidate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03820388

Layout table for location information
United States, California
University of California Davis Medical Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
Layout table for investigator information
Principal Investigator: Hong Liu, MD University of California, Davis
Layout table for additonal information
Responsible Party: University of California, Davis Identifier: NCT03820388    
Other Study ID Numbers: 909765
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: January 29, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of California, Davis:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General